tiprankstipranks
Trending News
More News >
Closing Bell Movers: RH jumps 20% after Q1 earnings beat
PremiumThe FlyClosing Bell Movers: RH jumps 20% after Q1 earnings beat
8d ago
Celldex says Phase 2 Barzolvolimab study met primary endpoint
Premium
The Fly
Celldex says Phase 2 Barzolvolimab study met primary endpoint
8d ago
Celldex’s Barzolvolimab Shows Promising Long-Term Efficacy in CSU: Analyst Recommends Buy with $64 Target
Premium
Ratings
Celldex’s Barzolvolimab Shows Promising Long-Term Efficacy in CSU: Analyst Recommends Buy with $64 Target
9d ago
Celldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
PremiumRatingsCelldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
1M ago
Celldex’s Strategic Advancements and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
Celldex’s Strategic Advancements and Promising Clinical Developments Drive Buy Rating
1M ago
Celldex price target lowered to $38 from $44 at UBS
Premium
The Fly
Celldex price target lowered to $38 from $44 at UBS
1M ago
Celldex reports Q1 EPS (81c), consensus (74c)
PremiumThe FlyCelldex reports Q1 EPS (81c), consensus (74c)
1M ago
Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
2M ago
Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
Premium
Ratings
Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100